CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Fresenius lifts 2026 expectations after strong Q3

By Reuters News

By Tristan Veyet, Kira Britten and Patricia Weiss

Nov 4 (Reuters) - Healthcare group Fresenius FREn.DE lifted its full-year expectations on Wednesday after reporting higher-than-anticipated third-quarter results, as strong performance at the Kabi and Helios divisions supported earnings.

The company now expects an earnings before interest and tax (EBIT) margin above 11.5%, compared with around 11.5% previously, and 2026 constant-currency core earnings per share (EPS) growth in the upper end of its 10%-15% range.

The latest guidance upgrade is Fresenius' second this year, after raising its core EPS target in August, as it seeks to improve profitability and reduce debt under CEO Michael Sen's turnaround strategy.

https://www.reuters.com/graphics/FRESENIUS-DEBT/GRAPHIC/bypraagqyve/chart.png

For the third quarter, Fresenius posted earnings before interests and taxes, and special items, of €638 million ($716 million), above the €618.5 million consensus compiled by Vara Research.

Fresenius Kabi generated €391 million in quarterly EBIT, slightly above the €388 million Vara Research consensus and representing more than 60% of the group total, as Kabi plays a growing role in Fresenius' strategy, particularly through its expanding biopharma business.

Hospital operator Helios also beat expectations, reporting EBIT of €293 million in the quarter, 6% above the Vara Research consensus of €277 million, helped by efficiency measures and improving profitability in Germany and Spain.

Fresenius' results contrast those of former unit Fresenius Medical Care FMEG.DE, in which it still owns a 25% stake, after the dialysis specialist cut its operating income outlook following a third consecutive quarterly decline in US treatment volumes.


($1 = 0.8905 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.